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Abst rac t
Introduction: The first therapeutic choice for food allergy is avoidance of the responsible food, but when this ap-
proach is not possible, specific oral desensitization could be considered as a good alternative. It is not clear yet 
whether the acquired tolerance is transient or persistent. 
Aim: We report on a subset of 13 patients of a larger study, treated successfully with specific oral tolerance induc-
tion who experienced secondary loss of tolerance after a period of allergen avoidance.
Material and methods: Thirteen patients affected by IgE-mediated food allergy: to cow milk (3 patients), to hen 
egg (3 patients), to cod fish (2 patients), to peanuts (1 patient) and to corn (1 patient) confirmed by a complete 
allergological workup and a double-blind placebo-controlled food challenge (DBPCFC), were treated with sublingual-
oral desensitization. After the interruption of the maintenance phase, the laboratory tests were performed and  
12 of 13 patients underwent DBPCFC. 
Results: Oral specific desensitization was completed successfully in all the 13 reported patients. At different times 
after the end of treatment, they decided, on their own initiative, to stop the ingestion of incriminated food. A new 
food allergen re-exposure caused adverse reactions in 12 of 13 patients. The detection of specific IgE and IgG4 
during the period of allergen avoidance showed an increase in or a stable level of specific IgE and a decrease in 
specific IgG4 in 8 patients.
Conclusions: According to our experience, the tolerance obtained through the desensitizing treatment is transient 
and so the regular allergen intake is necessary for its maintenance. 
Key words: food allergy, oral specific desensitization, follow-up, allergen avoidance, loss of tolerance, maintenance 
phase.
Introduction
Food allergy affects 1–4% of the general population 
[1]. The incidence of food allergy is age dependent, affect-
ing 6% to 8% of children under the age of 3 years and 5% 
of adult population [2, 3].
The first therapeutic choice for food allergy consists 
of strict avoidance of the culprit food by elimination diet 
[4]. This approach is not always possible, especially for 
basic foods (such as milk or egg), because they have an 
essential role in psychophysical wellbeing and their com-
plete exclusion from the diet is sometimes very difficult 
(for example in the case of hidden allergens) [5]. Fortu-
nately, loss of food hypersensitivity may occur in 19–67% 
of allergic patients within the first 3 to 5 years of life [6]. 
Some studies showed that the natural history of food 
allergy changes according to the culprit food; in fact it is 
common for milk, egg or soy and rare for peanuts, nuts, 
sesame seeds and fish [7, 8]. In the literature the data are 
not unambiguous. The study of Skripack suggested that 
milk allergy is more persistent and children reach a spon-
taneous tolerance in late childhood or adolescence (64% 
at 12 years) [9]. Lack reported spontaneous desensitiza-
tion for the egg, as appropriate in 66% of patients within 
5 years of age, 75% – aged 7 years and older, 33% – over 
16 years [10]. According to Sampson, spontaneous desen-
sitization occurs only in 20–25% of children with peanut 
allergy [11]. The Wood’s study found that the higher the 
baseline levels of specific IgE, the smaller is the chance 
that they can spontaneously reach tolerance [12].
Specific oral desensitizing treatment could be con-
sidered a good alternative for those patients who did not 
acquire clinical tolerance and cannot avoid the ingestion 
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of incriminated food. This therapeutic approach has been 
successfully adopted by several authors [13–19]. In our 
experience, the oral specific desensitizing treatment is 
successful in 83.3% of patients who completed the pro-
tocol [17]. Analyzing the data of our patients at the end of 
treatment, we observed a significant decrease in specific 
IgE and a significant increase in specific IgG4 levels; this 
appears to be in line with a switch from a Th2 to a Th1 
response [15, 18]. 
Indeed, the OIT immunological mechanisms are still 
not completely clarified. Low doses of the allergen seem 
to boost T reg cells inducible (CD25 + FoxP3 +) in the 
MALT tissue; this leads to a reduced Th2 response due 
to IL-10 e TGF-β production [20]. Exposure to high doses 
of the allergen may lead to anergy or clonal deletion of 
T cells [21].
In both cases it seems that in order to keep such level 
of tolerance, constant exposure to the allergen should be 
maintained. 
Some authors wondered whether the oral specific 
desensitization can induce transient or persistent toler-
ance in patients with food allergy [18, 19, 22, 23]. Most of 
them think that a regular allergen intake is necessary to 
maintain the oral tolerance [18, 19, 23]; whereas Staden 
et al. identified a group of children with food allergy (pat-
tern I – responder), who have successfully undergone 
oral specific desensitization and did not show any aller-
gic symptoms during the reintroduction of incriminated 
food after a period of avoidance [22]. 
Aim
Here we report on loss of tolerance in food-allergic 
patients, who, after successful oral desensitizing treat-
ment, have interrupted the regular allergen intake. In this 
paper we aim to evaluate the modification of specific IgE 
and IgG4 values in these patients at the end of desensi-
tization treatment.
Material and methods
We included 13 patients (7 females and 6 males; aged 
from 4 to 49 years) affected by IgE-mediated food allergy: 
to cow milk (CM: 5 patients), to hen egg (HE: 3 patients), 
to cod fish (CF: 2 patients), to peanut (PN: 1 patient), to 
corn (C: 1 patient) and to apple (A: 1 patient) confirmed 
by double-blind placebo-controlled food challenge 
(DBPCFC). All patients were treated with SOTI according 
to standardized protocols [17, 18]. In the induction phase 
(IP), the patients underwent SOTI starting with doses di-
luted in water and then undiluted up to a maximum dose 
administered (different for each type of food). This was 
followed by a maintenance phase (MP) with a minimum 
maintenance dose of 120 ml for CM, 35 g of HE protein 
(1 egg), 100 g for CF, 40 g for PN, 60 g for C and 180 g for 
A (1 apple) at least twice a week, plus deliberate additive 
intake. According to the protocol, all patients, and their 
parents in the case of children under 18 years of age, 
were well trained in medical treatment of allergic reac-
tions and equipped with an emergency kit: auto-inject-
able epinephrine, betamethasone and chlorphenamine 
and oral second-generation antihistamines (cetirizine, 
ebastine or loratadine). In the case of any side effects 
during the IP, the patients could use these therapies. 
During the IP, 2 patients experienced some mild side ef-
fects such as urticaria, angioedema and/or worsening 
of bronchial asthma so they were treated with oral H
1
-
antihistamine (cetirizine, ebastine or loratadine). 





were performed at the 
beginning (time 0) and at the end of desensitizing treat-
ment (time 1). 
Twelve of 13 patients underwent DBPCFC after the 
interruption of regular intake of allergenic food. 
Results
SOTI was completed successfully in all the 13 reported 
patients. When stratifying patients on the basis of food 
allergy, the results can be summarized as follows (Table 1).
Patients with milk allergy (1–5) completed successfully 
the IP in 4–12 months until the dose of 150 ml; then they 
continued drinking at least 120 ml of fresh pasteurized 
milk and eating dairy products as much as they liked with 
no problems in the maintenance phase (MP: 1–10 months).
In patients 6–8 with egg allergy, the maximum dose 
(1 egg) was reached in 3–9 months and the intake of one 
raw egg twice a week plus deliberate intake of meals con-
taining the allergen was continued for 9–15 months of the 
maintenance phase. 
Patients suffering from allergy to cod fish (9–10) be-
came tolerant to the maximum dose (100 g of cod fish) 
after 8–12 months of treatment, and they continued the 
maintenance dose (100 g of cod fish 3 times/week) for 
6–18 months.
Patient 11 with peanut allergy underwent oral rush 
desensitization to peanut protein, reaching the maximum 
dose of peanuts (40 g) after 9 days. She stopped the inges-
tion of the maintenance dose (40 g of peanuts 4 times/
week) after 2 months.
Patient 12 suffering from corn allergy reached the 
maintenance phase (60 g of corn 3 times/week) in 
3 months and that continued for 3 months.
Patient 13 with apple allergy, reached the dose of 
180 g of apples after 6 months and he continued it for 
12 months.
The patients themselves decided to discontinue 
the maintenance dose intake and were evaluated after 
a median of 6 months (minimum 1 month and maximum 
12 months) of allergen avoidance.
We decided to repeat allergological evaluation (spe-
cific IgE and IgG
4
 assessment and DBPCFC). The detec-
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tion of specific IgE and IgG
4
 during the period of aller-
gen avoidance showed an increase in or a stable level of 
specific IgE and a decrease in specific IgG4 in 8 patients.
DBPCFC was carried out in 12 patients, because 
one patient developed asthma only after inhalation of 
fish fumes and the OC was contraindicated. During the 
DBPCFC, 12 patients presented symptoms ranging from 
urticaria-angioedema to abdominal pain. In 1 case, a sys-
temic reaction (anaphylactic shock) was observed after 
the ingestion of 7.5 ml of egg. 
Twelve of 13 patients underwent DBPCFC after the 
interruption of regular intake of allergenic food and in 
4 cases, new desensitizing treatment was successfully 
completed. 
Discussion
To date therapeutic strategies in food allergy have 
been discussed controversially. The gold standard is strict 
elimination diet, but it is difficult in everyday life and it 
carries a risk of malnutrition. Furthermore, an elimination 
diet increases the risk of allergic reactions after acciden-
tal ingestion of the culprit food [12, 19]. Therefore, casual 
treatment is recommended.
The SOTI, in our experience, represents an alterna-
tive and safe approach in food allergic patients, who 
did not spontaneously acquire clinical tolerance and 
cannot avoid the ingestion of incriminated foods [13, 
17, 18, 24].
Whether the induced tolerance is of permanent or 
transient nature remains unclear. Some authors think, 
a regular allergen intake is necessary to maintain the es-
tablished tolerance whereas recently the Nurmatov meta-
analysis has led to a huge reduction in the severity of the 
reactions at the DBPCFC in the active group compared 
to the control group [18, 19, 23, 25]. Anyway, there are 
few studies showing the OIT ability to induce permanent 
tolerance [19, 23, 26, 27].
In this paper we have wanted to focus our attention 
on the acquired tolerance induced by the desensitiza-
tion and to show what happened in our 13 patients when 
they stopped, on their own initiative, the maintenance 
phase. Although they stopped the intake of incriminated 
food in different ways at different times, a new allergen 
re-exposure caused always the return of symptoms in all 
the 13 reported patients. However, it is interesting to note 
that the loss of tolerance occurred in patients affected by 
IgE-mediated allergy to different foods and the different 
allergenic proteins seem not to influence the natural his-
tory of food allergy. 
The average age of our patients who discontinued the 
maintenance dose was 19.5 years, therefore spontaneous 
desensitization is probability excluded since it typically 
occurs during the pediatric age. 
Moreover, our cases show that the tolerance does not 
depend on immunotherapy duration or a period of al-
lergen avoidance, but it is bound to the natural history 
and, most importantly, to the constant exposure to the 
Table 1. Description of patients' features
Patient Age/sex Allergen OIT period
[months]
Minimum maintenance 














1 18/female CM 7 120 ml 3 times/week 1 30 ml UA Anti-H1
2 20/male CM 4 120 ml 3 times/week 6 50 ml UA CS
3 19/female CM 4 120 ml 3 times/week 8 50 ml UA Anti-H1
4 24/male CM 12 120 ml 3 times/week 3 10 ml Dermatitis Anti-H1
5 4/male CM 12 120 ml 3 times/week 6 10 ml GS NA
6 7/female HE 9 1 HE 2 times/week 4 7.5 ml AS Epinephrine, 
CS
7 24/male HE 3 1 HE 2 times/week 1 2 g Itching, 
asthma
CS
8 20/female HE 5 1 HE 2 times/week 2 1 g UA CS
9 20/male CF 8 100 g 3 times/week 12 NA – –
10 12/female CF 12 100 g 3 times/week 2 30 g UA Anti-H1
11 49/female Peanut < 1 40 g 3 times/week 1.5 100 g GS CS
12 36/female Corn 3 60 g 3 times/week 2 10 g UA NA
13 13/male Apple 6 1 apple 3 times/week 2 87 g Itching, 
asthma
CS
CM – cow’s milk, HE – hen’s egg, CF – cod fish, UA – urticaria/angio-edema, AS – anaphylactic shock, GS – gastrointestinal symptoms, anti-H1 – antihistamine, 
CS – corticosteroids, NA – not administered.
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allergen. Indeed, if the exposure has not been constant, 
the immunotherapy effects might be temporary.
Confirming this observation, the DBPCFC, performed in 
12 of the 13 patients after the interruption of regular intake 
of allergenic food, was positive and one of our patient who 
spontaneously stopped the OIT, after 9-month therapy, had 
an anaphylactic shock, after the ingestion of culprit food.
One patient did not undergo the second DBPCFC, be-
cause he had developed important symptoms only after 
inhalation or touch of the incriminated food. The changes of 
allergen-specific IgE and IgG4 have been documented in all 
the patients. Analyzing the data of our patients at the end of 
treatment, we observed a significant decrease in specific IgE 
and a significant increase in specific IgG
4
 levels; this appears 
to be in line with a switch from a Th2 to a Th1 response. The 
increase in or a stable level of specific IgE and a decrease in 
specific IgG4 observed in 8 patients could be explained by 
a return of the switch from a Th1 to a Th2 response.
Although we believe it will be necessary to perform more 
in-depth studies on the causes concerning the loss of toler-
ance, we conclude that SOTI does not alter the natural out-
come of food allergy. It substantially induces the increase 
in the threshold dose necessary to elicit allergic symptoms, 
resulting in transient clinical tolerance. Until now, only little 
information has been available on the dosage intervals to 
preserve the acquired tolerance [28].
Therefore, a regular allergen intake is necessary for its 
maintenance. 
According to our experience, for safety reasons, the in-
take of culprit food should be recommended at least twice 
a week plus deliberate intake of meals containing the aller-
gen.
The OIT decreases the risk of allergic reactions in pa-
tients with severe food allergy, allows culprit food reintro-
duction and consequently life quality improvement, but 
the OIT main pitfall is the lack of standardized protocols. 
Conclusions
Further trials are needed to create OIT standardized 
protocols in order to boost security and to identify bio-
markers defining the patients that are in danger.
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